X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PLETHICO PHARMA VENUS REMEDIES/
PLETHICO PHARMA
 
P/E (TTM) x -807.5 -1.1 - View Chart
P/BV x 0.2 0.0 1,409.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PLETHICO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
PLETHICO PHARMA
Mar-14
VENUS REMEDIES/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs218395 55.2%   
Low Rs8231 262.3%   
Sales per share (Unadj.) Rs365.6604.4 60.5%  
Earnings per share (Unadj.) Rs1.532.5 4.6%  
Cash flow per share (Unadj.) Rs37.951.3 73.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.5473.6 80.8%  
Shares outstanding (eoy) m11.4434.08 33.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.4 116.4%   
Avg P/E ratio x101.06.6 1,539.0%  
P/CF ratio (eoy) x4.04.2 95.3%  
Price / Book Value ratio x0.40.5 87.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7177,262 23.6%   
No. of employees `0001.0NA-   
Total wages/salary Rs m3241,596 20.3%   
Avg. sales/employee Rs Th4,100.7NM-  
Avg. wages/employee Rs Th318.0NM-  
Avg. net profit/employee Rs Th16.7NM-  
INCOME DATA
Net Sales Rs m4,18320,598 20.3%  
Other income Rs m20386 5.2%   
Total revenues Rs m4,20320,984 20.0%   
Gross profit Rs m8122,818 28.8%  
Depreciation Rs m417642 64.9%   
Interest Rs m3801,593 23.8%   
Profit before tax Rs m35969 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18-138 -13.1%   
Profit after tax Rs m171,107 1.5%  
Gross profit margin %19.413.7 141.8%  
Effective tax rate %51.6-14.3 -360.9%   
Net profit margin %0.45.4 7.6%  
BALANCE SHEET DATA
Current assets Rs m2,77118,877 14.7%   
Current liabilities Rs m1,93111,896 16.2%   
Net working cap to sales %20.133.9 59.2%  
Current ratio x1.41.6 90.4%  
Inventory Days Days12536 348.0%  
Debtors Days Days54198 27.2%  
Net fixed assets Rs m5,3289,861 54.0%   
Share capital Rs m114341 33.6%   
"Free" reserves Rs m4,17712,331 33.9%   
Net worth Rs m4,37616,139 27.1%   
Long term debt Rs m1,9114,706 40.6%   
Total assets Rs m8,42833,146 25.4%  
Interest coverage x1.11.6 67.9%   
Debt to equity ratio x0.40.3 149.7%  
Sales to assets ratio x0.50.6 79.9%   
Return on assets %4.78.1 57.8%  
Return on equity %0.46.9 5.7%  
Return on capital %6.612.3 53.7%  
Exports to sales %021.4 0.0%   
Imports to sales %20.515.2 134.8%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs m8583,136 27.4%   
Fx inflow Rs m04,402 0.0%   
Fx outflow Rs m8583,184 27.0%   
Net fx Rs m-8581,219 -70.4%   
CASH FLOW
From Operations Rs m4692,437 19.2%  
From Investments Rs m29-6,265 -0.5%  
From Financial Activity Rs m-4642,490 -18.6%  
Net Cashflow Rs m35-1,337 -2.6%  

Share Holding

Indian Promoters % 32.9 82.7 39.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.3 4.2%  
FIIs % 0.6 5.5 10.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 7.5 885.3%  
Shareholders   20,121 10,665 188.7%  
Pledged promoter(s) holding % 36.4 85.7 42.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 21, 2017 12:31 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS